Pharmsynthez (MOEX:LIFE)
Russia · Delayed Price · Currency is RUB 4.505
+0.415 (10.15%)
At close: Jul 8, 2022
Pharmsynthez Income Statement
Financials in millions RUB. Fiscal year is January - December.
Millions RUB. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | 2013 - 2017 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | Dec '18 Dec 31, 2018 | 2013 - 2017 |
| - | 379.67 | 438.33 | 371.66 | 291.07 | 349.39 | Upgrade | |
Revenue Growth (YoY) | - | -13.38% | 17.94% | 27.68% | -16.69% | -51.38% | Upgrade |
Cost of Revenue | - | 295.21 | 280.94 | 211.74 | 262.41 | 263.84 | Upgrade |
Gross Profit | - | 84.46 | 157.39 | 159.92 | 28.66 | 85.55 | Upgrade |
Selling, General & Admin | - | 194.74 | 260.94 | 256.96 | 245.76 | 404.27 | Upgrade |
Research & Development | - | 16.8 | 54.18 | 46.02 | 5.77 | 69.6 | Upgrade |
Other Operating Expenses | - | -1.68 | -90.31 | -12.28 | -5.14 | -201.31 | Upgrade |
Operating Expenses | - | 210.42 | 384.94 | 307.28 | 246.39 | 272.56 | Upgrade |
Operating Income | - | -125.96 | -227.55 | -147.36 | -217.73 | -187.01 | Upgrade |
Interest Expense | - | -41.33 | -36.38 | -29.55 | -9.44 | -9.9 | Upgrade |
Interest & Investment Income | - | 0.1 | 3.04 | 2.26 | 1.83 | 0.47 | Upgrade |
Earnings From Equity Investments | - | -14.38 | -17.04 | -56.2 | -305.35 | -271.36 | Upgrade |
Currency Exchange Gain (Loss) | - | -8.58 | 18.69 | -104.71 | 84.56 | -82.29 | Upgrade |
Other Non Operating Income (Expenses) | - | -0.01 | -56.43 | -0.05 | -0.4 | -0.58 | Upgrade |
EBT Excluding Unusual Items | - | -190.15 | -315.66 | -335.61 | -446.53 | -550.66 | Upgrade |
Gain (Loss) on Sale of Investments | - | -19.49 | -388.56 | -196.11 | -1,577 | - | Upgrade |
Gain (Loss) on Sale of Assets | - | 0.92 | -29.18 | 4.51 | -4.89 | - | Upgrade |
Pretax Income | - | -208.72 | -733.4 | -527.21 | -2,029 | -550.66 | Upgrade |
Income Tax Expense | - | -1.22 | -35.85 | -2.4 | -217.13 | -132.96 | Upgrade |
Earnings From Continuing Operations | - | -207.49 | -697.55 | -524.81 | -1,812 | -417.7 | Upgrade |
Net Income | - | -207.49 | -697.55 | -524.81 | -1,812 | -417.7 | Upgrade |
Net Income to Common | - | -207.49 | -697.55 | -524.81 | -1,812 | -417.7 | Upgrade |
Shares Outstanding (Basic) | 440 | 301 | 301 | 301 | 301 | 301 | Upgrade |
Shares Outstanding (Diluted) | 440 | 301 | 301 | 301 | 301 | 301 | Upgrade |
Shares Change (YoY) | 46.30% | - | - | - | - | 9.01% | Upgrade |
EPS (Basic) | - | -0.69 | -2.32 | -1.74 | -6.02 | -1.39 | Upgrade |
EPS (Diluted) | - | -0.69 | -2.32 | -1.74 | -6.02 | -1.39 | Upgrade |
Free Cash Flow | - | -6.82 | -62.97 | -242.45 | -83.39 | -132.12 | Upgrade |
Free Cash Flow Per Share | - | -0.02 | -0.21 | -0.81 | -0.28 | -0.44 | Upgrade |
Gross Margin | - | 22.24% | 35.91% | 43.03% | 9.85% | 24.49% | Upgrade |
Operating Margin | - | -33.18% | -51.91% | -39.65% | -74.80% | -53.52% | Upgrade |
Profit Margin | - | -54.65% | -159.14% | -141.21% | -622.45% | -119.55% | Upgrade |
Free Cash Flow Margin | - | -1.80% | -14.37% | -65.23% | -28.65% | -37.81% | Upgrade |
EBITDA | - | -106.06 | -196.35 | -102.96 | -191.8 | -132.42 | Upgrade |
EBITDA Margin | - | -27.94% | -44.80% | -27.70% | -65.89% | -37.90% | Upgrade |
D&A For EBITDA | - | 19.9 | 31.2 | 44.4 | 25.94 | 54.59 | Upgrade |
EBIT | - | -125.96 | -227.55 | -147.36 | -217.73 | -187.01 | Upgrade |
EBIT Margin | - | -33.18% | -51.91% | -39.65% | -74.80% | -53.52% | Upgrade |
Advertising Expenses | - | 5.76 | 12.32 | 7.2 | 2.76 | 17.1 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.